Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report

Abstract

Objective: Triple negative and human epidermal growth factor receptor 2 (Her2) positive breast tumors are characterized by the absence of expression of estrogen and progesterone receptors and with either Her2 expression or not. Generally, they are larger tumors with higher grade, higher incidence of recurrence and distant metastasis. This article will investigate clinical, pathological, and molecular features of these high risk breast cancer patients and whether these features are correlated with recurrences or not. Materials and Methods:Breast cancer patients of 109 triple negative and 81 Her2 positive histology followed in the medical oncology department of our hospital between 2004 and 2011 were enrolled in the study. These patients were mostly treated with adjuvant and neoadjuvant chemotherapy. Results:The median age of patients was 51 and 52 years. Median follow-up duration was 22 and 29 months. Four patients in each group died during the follow-up. 5 year survival rates were 81.1% in triple negative group and 73.5% in Her2 positive group. Relapses were seen in 30 patients. Bone and brain were the most common metastatic sites in the first and second groups respectively. Triple negative patients having larger tumor size and Her2 positive patients having positive lymph node or not treated with radiotherapy have a statistically higher chance of relapse during the follow-up. Conclusion:Despite the short median follow-up time, approximately one sixth of our patients had recurrence and this supported the aggressive course of the disease in high risk patients. For this reason, risk factors that help us to predict the early recurrences in both of the groups are very important.Key words: Breast cancer, survival analysis, retrospective studies, recurrences ÖZET Amaç: Triple negatif ve insan epidermal büyüme faktör reseptörü 2 (Her2) pozitif meme tümörleri, östrojen ve progesteron reseptörlerinin negatif olması ve HER-2 ekspresyonun olup olmaması ile karakterizedir. Diğer meme kanserleri ile karşılaştırıldığında daha büyük ve daha yüksek dereceli tümörlerdir, erken nüks ve metastaz sıklığı daha fazladır. Bu yazıda yüksek riskli meme kanserlerinin klinik, patolojik ve moleküler özellikleri ve bu özelliklerin nüks ile ilişkisi araştırılacaktır. Sonuç: Kısa izlem süresine rağmen hastalarımızın yaklaşık altıda birinde nüks gözlenmesi, bu yüksek riskli hastalardaki agresif seyri desteklemektedir. Dolayısıyla her iki hasta grubunda da, hastalık nüksünü erken dönemde öngörülebilecek risk faktörlerinin saptanması önem taşımaktadır.Anahtar sözcükler: Meme kanseri, sağkalım analizi, retrospektif çalışmalar, nüks GirişMeme kanseri kadınlarda görülen kanserlerin en sık görülen türü olup yaklaşık %25-%30`unu oluşturmaktadır. Kansere bağlı mortalite (%18) ise akciğer kanserlerinden sonra ikinci sırada yer almaktadır (1). Meme kanseri 30 yaşından önce nadir görülmekle birlikte bu yaşı takip eden reprodüktif yıllarda hızlı bir artış gösterir. Bu artış menopoz sonrasında da yavaş eğimle yükselmeye devam eder (2).Son dönemlerde...

The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience

“…In addition data from a single institution series including some of the patients that constitutes a fraction of the patient group in this study; have reported a 5-year survival rate of 82.4% which was comparable to other hormone receptor negative disease when adjusted for known clinical factors such as age, stage, grade and nodal status (16). A recently published article from a single center in Turkey which included early triple-negative breast cancer patients also revealed a 81% five-year overall survival rate which was in concordance with our results (17 at similar DFS rates for both patient groups (18). Median overall survival rates could not be obtained but the 5-year DFS rates for TNBC and HER-2 positive patients were reported to be 67% and 66%, respectively which were slightly lower than our results.…”